Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure.

@article{Abraham2019MetaAnalysisCT,
  title={Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure.},
  author={Bishoy Abraham and Michael Megaly and Mina Sous and Mina Fransawyalkomos and Marwan Saad and Robert Fraser and Joel M. Topf and Steven R. Goldsmith and Mengistu A. Simegn and Bradley A. Bart and Zain Azzo and Nancy Mesiha and Rajaninder Sharma},
  journal={The American journal of cardiology},
  year={2019}
}
LOOP DIURETICS IN HEART FAILURE: EVIDENCE-BASED CHOICE.
TLDR
There is enough convincing evidence to speak about the advantages of torasemide over furosemide both in terms of its pharmacological properties and taking into account the reduction of hospitalizations, functional progress and improvement in the quality of life of patients with heart failure.
Role of loop diuretics in the treatment of acute heart failure
TLDR
The effect of torasemide on mortality reduction in patients with heart failure, seen in some studies, requires further evaluation, and the choice of optimal diuretic treatment strategy in acute heart failure requires knowledge about differences in the characteristics of loop diuretics available in Poland, furosemide and tor asemide.
Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization
TLDR
A practical guide for the implementation of these four pillars of GDMT during a hospitalization for acute heart failure: renin-angiotensin-aldosterone system inhibitors with or without a neprilysin inhibitor, β-blockers, mineralocorticoid-receptor-antagonists, and sodium-glucose cotransporter-2 inhibitors.
Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?
TLDR
Emerging new therapies in HFrEF could reduce the reliance on diuretics in the management of this phenotype of HF, and the emergence of sodium glucose transport 2 inhibitors and guanylate cyclase stimulators may further exemplify this issue.
Impact of Loop Diuretic on Outcomes in Patients with Heart Failure and Reduced Ejection Fraction
TLDR
Loop diuretic use is recommended in order to alleviate symptoms, improve exercise capacity, and reduce hospitalizations in patients with heart failure and their use should be limited to the lowest dose necessary to maintain euvolemia.
Pharmacotherapeutic principles of fluid management in heart failure
TLDR
Following an in-depth review of currently available pharmacological agents, the rationale and evidence behind their use, the authors end with a brief note on novel agents/approaches to aid volume management in HF.
The Ecology of Antihypertensives in the United States, 1997-2017
TLDR
Antihypertensive classes appear to have a propensity to equilibrate to an individual medication, despite a lack of outcomes based research to compare medications within a class.
The Ecology of Antihypertensives in the United States, 1997–2017
TLDR
Antihypertensive classes appear to have a propensity to equilibrate to an individual medication, despite a lack of outcomes-based research to compare medications within a class.
Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardiorenal Approach
TLDR
The pathophysiological mechanisms involved in cardiorenal syndrome and the interplay between heart failure and chronic kidney disease are reviewed and an integrated multimodal diagnostic algorithm is proposed.
...
...

References

SHOWING 1-10 OF 30 REFERENCES
Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.
TLDR
Patients treated with torsemide had features of greater disease severity, similar 30-day outcomes but increased 150-day mortality, and Prospective randomized trials are needed to investigate the effect of Torsemide versus furosemide.
Torsemide Versus Furosemide in Heart Failure Patients: Insights From Duke University Hospital
TLDR
Furosemide has historically been the primary loop diuretic in heart failure patients despite data suggesting potential advantages with torsemide, and the relationship with all-cause mortality through 5 years was assessed.
Torsemide versus furosemide after acute decompensated heart failure: a retrospective observational study
TLDR
Switching furosemide to torsemide after ADHF was not associated with reduced HF-related hospitalization compared to receiving an optimized furoSemide dose, and larger prospective clinical trials are needed to confirm the findings.
Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology
TLDR
Torasemide may have advantageous influence on NYHA class and long-term outcomes of HF patients, especially younger patients or those with dilated cardiomyopathy, but it needs further investigations in prospective randomised trials.
Can Torsemide and Combination of Loop Diuretics Improve Mortality in Patients with Chronic Heart Failure After Discharge?
TLDR
It was found that torsemide and the combination strategy had similar outcomes when compared with furosemide, and considering the lack of diuretic randomized clinical trials (RCTs) conducted with the aim of exploring the effect on mortality of different diuretics treatments, prospective trials are needed.
Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint.
TLDR
Treating patients suffering from congestive heart failure with torasemide improved clinical outcome and was more cost-effective than with furosemide, according to a cost-effectiveness analysis.
...
...